Industry News
2025 Instrumentation Industry Development Index Released at 2026 High-end Instrument Innovation and Development Forum
2026-04-01
2026-03-16
2026-03-12
2026-03-10
2026-02-27
2025-11-20
Current AffairsIntroduction
The global therapeutic landscape for sleep disorders has undergone a significant paradigm shift, moving away from traditional central nervous system depressants towards more targeted neurochemical interventions. At the forefront of this evolution is Lemborexant, a highly selective molecule that addresses the root neurobiology of wakefulness. For pharmaceutical procurement managers, formulation scientists, and clinical researchers, sourcing a reliable, high-purity Lemborexant active pharmaceutical ingredient (API) is critical for developing next-generation sleep therapeutics. This comprehensive guide outlines the chemical profile, stringent quality parameters, and clinical applications of our premium API to support your drug development pipeline.
Lemborexant is an innovative, small-molecule competitive antagonist that specifically targets the orexin signaling system. Officially identified by its registry number, CAS 1369764-02-2, this compound is structurally designed to block the binding of wake-promoting neuropeptides (orexin A and orexin B) to their respective receptors, OX1R and OX2R.
Unlike traditional benzodiazepines or Z-drugs that induce sleep through broad GABAergic inhibition—often leading to next-day grogginess and dependency—Lemborexant works by temporarily suppressing the exact neurological signals that keep the brain awake.
Chemical Formula: C22H20F2N4O2
Molecular Weight: 410.42 g/mol
Chemical Name: (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide
For laboratories scaling up their formulation processes, securing a fully verified Lemborexant Dual Orexin Receptor Antagonist API guarantees that the raw material exhibits the exact stereochemistry and receptor affinity required for maximum clinical efficacy.
Appearance: White to off-white crystalline powder.
Stereochemical Purity: Chiral HPLC verifies the exact (1R,2S) configuration, preventing reduced efficacy from racemic impurities.
Residual Solvents: Strictly controlled according to ICH Q3C guidelines.
Polymorphism: Engineered and verified via X-Ray Powder Diffraction (XRPD) to ensure the correct, highly stable crystalline form for solid oral dosage formulations.
Core Parameters Overview:
| Test Item | Specification Limit | Test Method |
| Identification | Conforms to reference standard | NMR / IR |
| Purity (HPLC) | ≥ 99.5% | In-house / USP |
| Single Unknown Impurity | ≤ 0.1% | HPLC |
| Water Content (KF) | ≤ 0.5% | Karl Fischer |
| Residue on Ignition | ≤ 0.1% | USP/EP |
| Heavy Metals | ≤ 10 ppm | ICP-MS |
All commercial batches are provided with a complete Certificate of Analysis (COA), HPLC chromatograms, and detailed analytical testing data.
The pharmaceutical application of Lemborexant represents a targeted approach to managing sleep-wake cycles. Its unique pharmacokinetic profile allows for rapid onset of action and a half-life that correlates perfectly with a standard 7-to-8-hour sleep period, minimizing residual morning drowsiness.
Treatment of Adult Insomnia: The primary indication for this compound is the formulation of the Lemborexant API For Adult Insomnia Treatment. It is highly effective for patients struggling with sleep onset (falling asleep) as well as sleep maintenance (staying asleep throughout the night).
Geriatric Sleep Disorder Management: Clinical data suggests that Lemborexant has a favorable safety profile in older adults, showing a reduced risk of postural instability (falls) and cognitive impairment compared to traditional hypnotics. This makes the API highly valuable for R&D focusing on geriatric formulations.
Irregular Sleep-Wake Rhythm Disorders (ISWRD): Ongoing clinical trials and specialized R&D are exploring the use of Lemborexant in patients with circadian rhythm disruptions, including those associated with neurodegenerative diseases like Alzheimer's.
Q1: What are the optimal storage conditions for Lemborexant API?
To maintain its chemical stability and prevent degradation, Lemborexant API should be stored in a well-closed container at controlled room temperature (20°C to 25°C). It is crucial to protect the powder from excessive humidity and direct light.
Disclaimer: This website respects intellectual property rights. If any infringement is found, please contact this website in a timely manner for handling.
Our hours